FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

United Therapeutics Tyvaso Recall

TYVASO (treprostinil) Inhalation Solution Treprostinil 1

United Therapeutics Corp. · Durham, NC

Risk level
Class II
Reported by FDA
Nov 29, 2017
Recall ID
D-0083-2018
Check your lot numberHow we source this data

Summary

United Therapeutics recalled Tyvaso starting Sep 11, 2017. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0083-2018 on Nov 29, 2017. Reason: CGMP Deviations. Status: Terminated.

Why it was recalled

CGMP Deviations

Product description

TYVASO (treprostinil) Inhalation Solution Treprostinil 1.74 mg/2.9 mL (0.6 mg/mL) Tyvaso Inhalation System Starter Kit Model# TD-100/A, Rx Only, Manufactured by United Therapeutics Corporation Research Triangle Park, NC 27709, NDC# 6630220601

Lot numbers, UPCs & expiration codes

Lot #: 2101152; Exp. 12/11/2017 Lot #: 2101195; Exp. 04/26/2019

Where it was sold

PA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0083-2018
Classification
Class II
Status
Terminated
Recall initiated
Sep 11, 2017
FDA report date
Nov 29, 2017
Quantity
12 devices
Recall type
Voluntary: Firm initiated
Recalling firm
United Therapeutics Corp.

Original FDA data

Every field from FDA enforcement report D-0083-2018, exactly as published.

Show all FDA fields
City
Durham
State
NC
Status
Terminated
Country
United States
Event ID
78170
Address
55 Tw Alexander Dr
Code information
Lot #: 2101152; Exp. 12/11/2017 Lot #: 2101195; Exp. 04/26/2019
Postal code
27709-0152
Report date
Nov 29, 2017
Product type
Drugs
Recall number
D-0083-2018
Classification
Class II
Recalling firm
United Therapeutics Corp.
Product quantity
12 devices
Termination date
Apr 3, 2019
Reason for recall
CGMP Deviations
Voluntary / mandated
Voluntary: Firm initiated
Product description
TYVASO (treprostinil) Inhalation Solution Treprostinil 1.74 mg/2.9 mL (0.6 mg/mL) Tyvaso Inhalation System Starter Kit Model# TD-100/A, Rx Only, Manufactured by United Therapeutics Corporation Research Triangle Park, NC 27709, NDC# 6630220601
Distribution pattern
PA
Recall initiation date
Sep 11, 2017
Initial firm notification
Letter
Center classification date
Nov 19, 2017

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0083-2018, published Nov 29, 2017. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls